Aclaris Therapeutics (ACRS) Cash from Restructuring (2016)

Aclaris Therapeutics' (ACRS) quarterly Cash from Restructuring came in at $2.8 million in Q1 2016.

Aclaris Therapeutics (ACRS) Cash from Restructuring (2016) Analysis & Trends

Aclaris Therapeutics' Cash from Restructuring history runs 1 years deep, the most recent figure standing at $2.8 million for Q1 2016.

On a quarterly basis, Cash from Restructuring changed N/A year-over-year to $2.8 million in Q1 2016; TTM through Dec 2016 was $2.8 million, a N/A change from a year earlier, with the FY2016 full-year figure at $2.8 million, changed N/A from the prior year.
Cash from Restructuring held at $2.8 million in Q1 2016 per ACRS's latest filing.
Across five years, Cash from Restructuring topped out at $2.8 million in Q1 2016 and bottomed at $2.8 million in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Aclaris Therapeutics	705.88 Mn	705.88 Mn	1.60 Mn

Download Data

Date	Value
Mar 31, 2016	2.78 Mn